10-Q: Hims & Hers Health Reports Q2 2026 Results, Net Loss Widens

Hims & Hers Health, Inc. reported a net loss of $86.3 million for the three months ended June 30, 2026, a significant increase from the net income of $42.5 million in the prior year period, driven by higher operating expenses and a lower gross margin.

Summary

• Hims & Hers Health, Inc. reported a net loss of $86.3 million for the three months ended June 30, 2026, compared to a net income of $42.5 million in the same period last year.
• Revenue increased by 38% to $753.2 million for the three months ended June 30, 2026, compared to $544.8 million in the prior year period.
• Cost of revenue increased by 112% to $272.4 million, leading to a gross profit of $480.8 million, a 16% increase.
• Gross margin decreased to 64% from 76% in the prior year period, primarily due to higher costs associated with weight loss offerings and recent acquisitions.
• Total operating expenses increased by 48% to $578.0 million, driven by higher marketing, operations and support, technology and development, and general and administrative expenses.
• General and administrative expenses saw a significant increase of 146% to $165.4 million, largely due to $47.5 million in legal contingencies.
• The company completed the acquisition of Eucalyptus for $968.5 million and YourBio Health, Inc. for $153.0 million during the period.
• Cash and cash equivalents increased to $609.8 million as of June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to a significant net loss, increased operating expenses, and a substantial decrease in gross margin, despite revenue growth.

Positives

• Total revenue increased by 38% to $753.2 million for the three months ended June 30, 2026.
• Subscribers grew by 19% to approximately 2.9 million as of June 30, 2026.
• Monthly Revenue per Average Subscriber increased by 21% to $92 for the three months ended June 30, 2026.
• The company has $609.8 million in cash and cash equivalents and $231.2 million in short-term available-for-sale investments as of June 30, 2026.
• The company completed two significant acquisitions: Eucalyptus and YourBio Health, Inc., expanding its global reach and technology portfolio.

Negatives

• Net loss for the three months ended June 30, 2026, was $86.3 million, a significant deterioration from a net income of $42.5 million in the prior year period.
• Gross margin decreased from 76% to 64% due to increased cost of revenue, particularly related to weight loss offerings and acquisitions.
• Total operating expenses increased by 48% to $578.0 million, outpacing revenue growth.
• General and administrative expenses increased by 146% to $165.4 million, heavily impacted by $47.5 million in legal contingencies.
• The company reported a net loss of $178.4 million for the six months ended June 30, 2026, compared to a net income of $91.9 million in the prior year period.
• Cost of revenue more than doubled (112% increase) for the three-month period.
• The company has an accumulated deficit of $292.2 million as of June 30, 2026.

Risks

• The company faces significant legal proceedings, including an FTC complaint alleging violations of consumer protection laws, with a $60 million contingency accrual.
• The company is subject to evolving legal and regulatory environments in healthcare, telehealth, pharmacy, and data privacy, with potential for substantial penalties.
• Expansion into international markets introduces business, political, legal, regulatory, operational, financial, and economic risks.
• The company's reliance on third-party suppliers and potential supply chain disruptions could impact its ability to fulfill customer orders.
• The company's dual-class stock structure concentrates voting power, limiting investor influence.
• The company's investments in artificial intelligence may not yield expected benefits and could introduce new risks.
• The company faces intense competition from established healthcare providers, retailers, and technology companies.
• The company's brand reputation could be harmed by negative publicity, security breaches, or failure to meet customer expectations.

Future Outlook

The company expects to continue investing in growth, including fulfillment, distribution, operating capabilities, marketing, product offerings, and AI capabilities. While these investments are expected to increase operating expenses in the short term, the company anticipates they will positively impact results in the long term. Gross margin is expected to remain below comparative periods in the near term due to the strategic shift in weight loss offerings and recent international acquisitions, but is expected to stabilize over the long term.

Management Comments

• We believe that we have the technical infrastructure, distributed provider network, and access to clinical capabilities to lead the migration of routine office visits to a personalized, digital, accessible format.
• Our management primarily uses the Subscribers and Monthly Revenue per Average Subscriber metric to manage and monitor the performance of our business.
• We expect our gross margin to remain below comparative periods in the near term, primarily as a result of the 2026 US WL Announcement and recent international acquisitions.

Industry Context

StockSavvy.ai notes that Hims & Hers is operating in the rapidly growing digital health and telehealth sector. The company's significant revenue growth, particularly in international markets due to acquisitions, aligns with broader industry trends of digital transformation in healthcare. However, the increased operating expenses and declining gross margins highlight the competitive pressures and cost challenges within this sector, especially concerning customer acquisition and the cost of goods sold for specialized offerings like weight loss treatments.

Comparison to Industry Standards

• Hims & Hers' revenue growth of 38% year-over-year for the quarter is strong, but its gross margin decline from 76% to 64% is a concern compared to industry averages for direct-to-consumer health platforms, which often aim for higher margins through efficient supply chains and product mix.
• The significant increase in operating expenses, particularly marketing and G&A, is a common trend for growth-stage companies in the digital health space, but the magnitude of the increase (48% for total operating expenses) and the impact of legal contingencies on G&A warrant close monitoring.
• Competitors like Teladoc Health and Amwell also face challenges in balancing growth with profitability, often investing heavily in technology and market expansion, which can lead to periods of net losses.

Legal Proceedings

• Federal Trade Commission (FTC) investigation regarding privacy, advertising, subscription, and cancellation practices; FTC filed a complaint on July 29, 2026, alleging violations of FTC Act and ROSCA, seeking injunction and monetary relief. A $60 million legal contingency accrual has been recorded.
• Putative class action lawsuit (Doe v. Hims & Hers Health, Inc.) filed in U.S. District Court for the Northern District of California, alleging violations of privacy and consumer protection laws.
• Therapeutic Goods Administration (TGA) issued compulsory notices to Eucalyptus subsidiaries regarding advertising of prescription medicines.
• Putative securities class action lawsuit (In re Hims & Hers Health, Inc. Securities Litigation) filed, alleging misrepresentations regarding business and relationship with Novo Nordisk.
• Putative shareholder derivative lawsuits filed against directors and executives related to matters alleged in the Securities Action.

Related Party Transactions

• Payments made to Woolly Labs, Inc. (d/b/a Vouched) for identity verification services were $1.3 million and $2.7 million for the three and six months ended June 30, 2025, respectively. Vouched is no longer considered a related party as of July 1, 2025.

Stakeholder Impact

• Shareholders may experience continued stock price volatility due to the company's net loss, increased expenses, and ongoing legal proceedings.
• Employees may be impacted by the company's strategic shifts and investments, potentially affecting job security or growth opportunities.
• Customers may face changes in service offerings or pricing due to the company's strategic initiatives and acquisitions.
• Suppliers and partners may be affected by the company's expanded global operations and integration of acquired businesses.

Next Steps

• Continue to invest in fulfillment, distribution, and operating capabilities.
• Continue to invest in marketing to acquire new customers across all brands.
• Continue to invest in product offerings and customer experience.
• Continue to invest in artificial intelligence capabilities.
• Pursue opportunities to acquire or invest in complementary businesses, services, and technologies.
• Finalize purchase price allocations for recent acquisitions (Eucalyptus by Q2 2027, YourBio by Q1 2027, Zava by Q3 2026, Medici by Q4 2026).

Key Dates

Recommendation

The company's financial performance has significantly deteriorated, with a substantial net loss and declining gross margins, driven by increased operating expenses and legal contingencies. While revenue growth is present, it is not translating into profitability. The ongoing legal challenges and the strategic shift in weight loss offerings introduce considerable uncertainty. Given these factors, a cautious approach is warranted, suggesting a sell or hold recommendation until a clear path to profitability and resolution of legal issues is demonstrated.

Keywords

telehealth, weight loss, dermatology, hair loss, mental health, pharmacy, acquisitions, GLP-1